Aebi Schmidt Holding AG
AEBIAebi Schmidt Holding AG's price has outrun its earnings. +37.6% in a year against EPS −77.6% — the market is paying now for delivery later.
The sharpest disagreement: the price moved +37.6% in a year while annual EPS moved −77.6% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is between stages while the P/E sits at the 95th percentile of its own 1-year range. Underneath, the last four quarters read improving, and 220% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Aebi Schmidt Holding AG trades at $13.4, between stages. That is +6.8% against its own 200-day average. It sits at 64% of a 52-week range of $9 to $16. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 4 straight weeks.
Today the stock is between stages. At $13.4 it trades +6.8% versus its 200-day average and sits at 64% of its 52-week range ($9–$16).
Against the market, two honest reads. Cumulative: over the last 1.1 years the stock moved +21% while the S&P 500 moved +24% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 4 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Aebi Schmidt Holding AG trades at 108.5× P/E, at the pricey end of its own range (95th percentile). Its long-run median P/E is 79.8×, measured across 1.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 108.5× is at the pricey end of its own range (95th percentile), against a long-run median of 79.8× measured over 1.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −77.6% against a +37.6% price move — the price outran earnings, pushing the multiple UP its own range.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Aebi Schmidt Holding AG reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 6 quarters across 1 curve, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +40.4% | — | — | — |
| Profit | −66.7% | — | — | — |
| EPS | −77.6% | — | — | — |
| Stock price | +37.6% | — | — | — |
4-Factor Sector Score
41.1/100 — rank 15 of 21 in Farm & Heavy Construction Machinery · 65% evidence confidence
Aebi Schmidt Holding AG scores 41.1 out of 100 against the 21 companies it is compared with in Farm & Heavy Construction Machinery, ranking 15. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 14.6 + 9.3 + 8.8 + 8.4 = 41.1. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Aebi Schmidt Holding AG reported $0.5 B of revenue in the Mar 26 quarter, +84.0% year on year. That is the 4th straight quarter of year-on-year growth. Over 2 years it has compounded at 22.5% a year. The last full year, FY25, came in at $1.5 B. The last four reported quarters add to $1.7 B.
FY25 revenue came in at $1.5 B (+40.4% on the year), capping 2 years at 22.5% compound. The latest quarter (Mar 26) printed $0.5 B, +84.0% year on year — the 4th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +61.3% growth against the decade's 22.5% — the current year is running faster than its own long-run rate.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Aebi Schmidt Holding AG's operating margin is 4.3% in the Mar 26 quarter, +0.3 percentage points against the same quarter a year ago. Across 3 fiscal years the operating margin has ranged 4.6% to 6.4%. The current quarter is running below every full year in that window.
The latest quarter's operating margin is 4.3%, +0.3 pp against the same quarter a year ago. Across 3 fiscal years the operating margin has ranged 4.6%–6.4%.
Why the margin moved: operating margin went +0.3 pp year on year while gross margin went −0.4 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Aebi Schmidt Holding AG earned $0.0 B of net profit in the Mar 26 quarter. Full-year FY25 profit was $0.0 B. The 2-year compound rate is 0.0%. That is 0.0% of the quarter's revenue. The same quarter a year earlier earned $0.0 B.
Mar 26 profit was $0.0 B, null year on year. On the full year, FY25 printed $0.0 B (−66.7%), and the 2-year compound rate is 0.0%.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 220% of Aebi Schmidt Holding AG's reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $0.0 B of operating cash against $0.0 B of profit. After $0.0 B of capital spending, $−0.0 B was left as free cash.
FY25: operating cash of $0.0 B against reported profit of $0.0 B, leaving free cash of $−0.0 B after $0.0 B of capital spending. Across the last 3 fiscal years the conversion rate is 220% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Aebi Schmidt Holding AG does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Aebi Schmidt Holding AG earns a ROE of 1% in FY25. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 0.7% net margin on 0.76× asset turns.
FY25 ROE is 1%.
Why the return is what it is — the wiring (FY25): 0.7% net margin × 0.76× asset turns × 2.48× balance-sheet leverage ≈ 1.3% on equity. Margin does its share; leverage is a meaningful part of the equation.
Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.
Aebi Schmidt Holding AG has 3 quarters of declared dividends on file — too few for a trailing-twelve-month figure. The most recent declaration was $0.03 for Mar 26.
Aebi Schmidt Holding AG has declared a dividend in 3 of the last 9 reported quarters, most recently $0.03 for Mar 26. That is fewer than four quarters, so no trailing-twelve-month total is shown rather than one built from a partial year.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Aebi Schmidt Holding AG carries total debt of $0.8 B against shareholder equity of $0.8 B as of Mar 26, a debt-to-equity of 0.98. On the annual view that ratio went from 1.50 in FY23 to 0.94 in FY25. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of $0.8 B against shareholder equity of $0.8 B — a debt-to-equity of 0.98. On the annual view, debt-to-equity went from 1.50 (FY23) to 0.94 (FY25). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
4.5% of Aebi Schmidt Holding AG's tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 5.6 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 4.5% of the float is sold short, and at typical trading volumes it would take about 5.6 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Aebi Schmidt Holding AG: the Z-score reads 1.77. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits inside the distress zone. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
🚨 Why it matters: a Z-score of 1.77 is inside the distress zone — the balance sheet is a real risk, not a detail.
The safety line in one sentence: the Z-score reads 1.77.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Blue Bird CorporationBLBD | 64.3/100Mixed-positive evidence81% evidence | LEADER | 20.3/35 Revenue 10.1% · PAT 21.1% · OPM change 1.7 pp 83% evidence | 14.4/25 ROCE 10.4% · OPM 11.1% 76% evidence | 15.2/20 P/E 13.5× · PEG 0.52 65% evidence | 14.4/20 RS sector 17.8% · RS bench 16.8% · 1Y 40.6%11 of 12 weeks ahead 100% evidence |
| Exact sum: 20.3 + 14.4 + 15.2 + 14.4 = 64.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Federal Signal CorporationFSS | 62.4/100Thin evidence · provisional58% evidence | TURNING | 22.3/35 Revenue — · PAT — · OPM change 1.7 pp 45% evidence | 16.2/25 ROCE 6.3% · OPM 15.9% 76% evidence | 9.9/20 P/E 27.7× · PEG — 15% evidence | 14.0/20 RS sector 3.4% · RS bench 2.2% · 1Y 5.7%2 of 12 weeks ahead 100% evidence |
| Exact sum: 22.3 + 16.2 + 9.9 + 14 = 62.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 3Caterpillar Inc.CAT | 60.5/100Mixed-positive evidence81% evidence | FADING | 23.3/35 Revenue 11.8% · PAT -5.8% · OPM change -0.4 pp 83% evidence | 16.1/25 ROCE 5.5% · OPM 17.7% 76% evidence | 8.1/20 P/E 35.3× · PEG 1.72 65% evidence | 13.0/20 RS sector 15.7% · RS bench 15.1% · 1Y 110.4%9 of 12 weeks ahead 100% evidence |
| Exact sum: 23.3 + 16.1 + 8.1 + 13 = 60.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4PACCAR IncPCAR | 60.3/100Thin evidence · provisional58% evidence | TURNING | 19.5/35 Revenue — · PAT — · OPM change -1.9 pp 45% evidence | 12.6/25 ROCE 2.7% · OPM 10% 76% evidence | 10.1/20 P/E 25.2× · PEG — 15% evidence | 18.1/20 RS sector 8.9% · RS bench 7.7% · 1Y 39.6%2 of 12 weeks ahead 100% evidence |
| Exact sum: 19.5 + 12.6 + 10.1 + 18.1 = 60.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5Deere & CompanyDE | 57.2/100Mixed-positive evidence85% evidence | TURNING | 15.9/35 Revenue 4% · PAT -15.7% · OPM change -2 pp 95% evidence | 16.1/25 ROCE 4.3% · OPM 22.5% 76% evidence | 11.8/20 P/E 32.7× · PEG 1.03 65% evidence | 13.4/20 RS sector 4.9% · RS bench 3.7% · 1Y 21%1 of 12 weeks ahead 100% evidence |
| Exact sum: 15.9 + 16.1 + 11.8 + 13.4 = 57.2 · Decision use: Price leads the evidence: RS versus the benchmark is 3.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 6The Manitowoc Company, Inc.MTW | 52.6/100Mixed-positive evidence68% evidence | TURNING | 18.0/35 Revenue 5.2% · PAT -82.6% · OPM change -0.5 pp 62% evidence | 6.0/25 ROCE 0.2% · OPM 0.6% 76% evidence | 14.0/20 P/E 58.3× · PEG 0.14 65% evidence | 14.6/20 RS sector 7.5% · RS bench 6.3% · 1Y 38.3%2 of 12 weeks ahead 70% evidence |
| Exact sum: 18 + 6 + 14 + 14.6 = 52.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Oshkosh CorporationOSK | 51.6/100Thin evidence · provisional58% evidence | TURNING | 16.0/35 Revenue — · PAT — · OPM change -4.1 pp 45% evidence | 13.2/25 ROCE 3.4% · OPM 3.5% 76% evidence | 10.6/20 P/E 17.6× · PEG — 15% evidence | 11.8/20 RS sector 1% · RS bench -0.5% · 1Y 16.6%1 of 12 weeks ahead 100% evidence |
| Exact sum: 16 + 13.2 + 10.6 + 11.8 = 51.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8Alamo Group Inc.ALG | 47.4/100Mixed-negative evidence81% evidence | BASING | 16.3/35 Revenue 2.3% · PAT -12.2% · OPM change -1.3 pp 83% evidence | 13.7/25 ROCE 3% · OPM 10.1% 76% evidence | 10.4/20 P/E 19.7× · PEG 1.36 65% evidence | 7.0/20 RS sector -13.2% · RS bench -14.6% · 1Y -23.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.3 + 13.7 + 10.4 + 7 = 47.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Terex CorporationTEX | 46.4/100Thin evidence · provisional58% evidence | ASLEEP | 15.2/35 Revenue — · PAT — · OPM change -10.3 pp 45% evidence | 10.8/25 ROCE 2.8% · OPM -4.7% 76% evidence | 9.3/20 P/E 36.9× · PEG — 15% evidence | 11.1/20 RS sector 3.8% · RS bench 2.6% · 1Y 36%2 of 12 weeks ahead 100% evidence |
| Exact sum: 15.2 + 10.8 + 9.3 + 11.1 = 46.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10Columbus McKinnon CorporationCMCO | 45.3/100Thin evidence · provisional52% evidence | TURNING | 13.6/35 Revenue — · PAT — · OPM change -37 pp 45% evidence | 6.0/25 ROCE -0.6% · OPM -35% 76% evidence | 8.7/20 P/E 82.1× · PEG — 15% evidence | 17.0/20 RS sector 21% · RS bench 19.4% · 1Y 55.3%2 of 12 weeks ahead 70% evidence |
| Exact sum: 13.6 + 6 + 8.7 + 17 = 45.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11CNH Industrial N.V.CNH | 44.7/100Mixed-negative evidence81% evidence | BASING | 12.7/35 Revenue -4% · PAT -62.5% · OPM change -3.8 pp 83% evidence | 10.3/25 ROCE 1% · OPM 9.9% 76% evidence | 14.0/20 P/E 35.5× · PEG 0.46 65% evidence | 7.7/20 RS sector -4.9% · RS bench -6.2% · 1Y -9.7%1 of 12 weeks ahead 100% evidence |
| Exact sum: 12.7 + 10.3 + 14 + 7.7 = 44.7 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 12Wabash National CorporationWNC | 43.4/100Thin evidence · provisional52% evidence | BREAKING OUT | 11.3/35 Revenue — · PAT — · OPM change -99.9 pp 45% evidence | 5.2/25 ROCE -2.7% · OPM -17.3% 76% evidence | 11.3/20 P/E 1.7× · PEG — 15% evidence | 15.6/20 RS sector 15.3% · RS bench 13.4% · 1Y 25.9%9 of 12 weeks ahead 70% evidence |
| Exact sum: 11.3 + 5.2 + 11.3 + 15.6 = 43.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13Astec Industries, Inc.ASTE | 43.1/100Mixed-negative evidence75% evidence | ASLEEP | 18.4/35 Revenue 11.5% · PAT 73.3% · OPM change -3.9 pp 83% evidence | 6.7/25 ROCE 1% · OPM 2.3% 76% evidence | 11.7/20 P/E 48.1× · PEG 1.01 65% evidence | 6.3/20 RS sector -6.8% · RS bench -8% · 1Y 21%0 of 12 weeks ahead 70% evidence |
| Exact sum: 18.4 + 6.7 + 11.7 + 6.3 = 43.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14AGCO CorporationAGCO | 42.7/100Thin evidence · provisional58% evidence | BASING | 20.5/35 Revenue — · PAT — · OPM change 1 pp 45% evidence | 9.8/25 ROCE 1.7% · OPM 3.4% 76% evidence | 11.0/20 P/E 16.6× · PEG — 15% evidence | 1.4/20 RS sector -14.2% · RS bench -15.3% · 1Y -2.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 20.5 + 9.8 + 11 + 1.4 = 42.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 15Aebi Schmidt Holding AGthis pageAEBI | 41.1/100Mixed-negative evidence65% evidence | TURNING | 14.6/35 Revenue 61.2% · PAT -60.9% · OPM change -2.4 pp 83% evidence | 9.3/25 ROCE 1.3% · OPM 3.4% 76% evidence | 8.8/20 P/E 80.9× · PEG — 15% evidence | 8.4/20 RS sector -2.3% · RS bench -3.6% · 1Y 20.2%6 of 12 weeks ahead 70% evidence |
| Exact sum: 14.6 + 9.3 + 8.8 + 8.4 = 41.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Gencor Industries, Inc.GENC | 38.7/100Mixed-negative evidence75% evidence | BASING | 10.9/35 Revenue -10.3% · PAT -7.1% · OPM change -4.5 pp 83% evidence | 11.0/25 ROCE 2% · OPM 12.5% 76% evidence | 11.4/20 P/E 17× · PEG 1.32 65% evidence | 5.4/20 RS sector -9.1% · RS bench -10.2% · 1Y -2%0 of 12 weeks ahead 70% evidence |
| Exact sum: 10.9 + 11 + 11.4 + 5.4 = 38.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Titan International, Inc.TWI | 38.1/100Thin evidence · provisional52% evidence | BASING | 16.7/35 Revenue — · PAT — · OPM change -5.1 pp 45% evidence | 7.0/25 ROCE 1.1% · OPM -2.7% 76% evidence | 10.9/20 P/E 16.8× · PEG — 15% evidence | 3.5/20 RS sector -16.4% · RS bench -17.7% · 1Y -8.7%0 of 12 weeks ahead 70% evidence |
| Exact sum: 16.7 + 7 + 10.9 + 3.5 = 38.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 18Lindsay CorporationLNN | 37.0/100Mixed-negative evidence79% evidence | TURNING | 11.7/35 Revenue -7.1% · PAT -27.3% · OPM change -2.5 pp 95% evidence | 13.1/25 ROCE 2.7% · OPM 11.5% 76% evidence | 7.3/20 P/E 21× · PEG 2.04 65% evidence | 4.9/20 RS sector -12.2% · RS bench -13.5% · 1Y -13.4%0 of 12 weeks ahead 70% evidence |
| Exact sum: 11.7 + 13.1 + 7.3 + 4.9 = 37 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19CEA Industries Inc.BNC | 27.1/100Thin evidence · provisional52% evidence | ASLEEP | 9.6/35 Revenue — · PAT — · OPM change -2254.1 pp 45% evidence | 3.0/25 ROCE -43.5% · OPM -992.9% 76% evidence | 11.5/20 P/E 1.2× · PEG — 15% evidence | 3.0/20 RS sector -63.9% · RS bench -65.1% · 1Y -85.3%0 of 12 weeks ahead 70% evidence |
| Exact sum: 9.6 + 3 + 11.5 + 3 = 27.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Hyster-Yale, Inc.HY | 22.6/100Adverse evidence65% evidence | BASING | 4.1/35 Revenue -12.2% · PAT -175.7% · OPM change -5.8 pp 83% evidence | 4.1/25 ROCE -2.8% · OPM -3.5% 76% evidence | 8.5/20 P/E 263.3× · PEG — 15% evidence | 5.9/20 RS sector -8.2% · RS bench -9.3% · 1Y -2.4%2 of 12 weeks ahead 70% evidence |
| Exact sum: 4.1 + 4.1 + 8.5 + 5.9 = 22.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21SunScout Holding LimitedSNSC | 55.7/100Thin evidence · provisional11% evidence | 17.5/35 Revenue — · PAT — · OPM change — 0% evidence | 18.2/25 ROCE 30.5% · OPM — 46% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence | |
| Exact sum: 17.5 + 18.2 + 10 + 10 = 55.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Aebi Schmidt Holding AG's stock price today?
Aebi Schmidt Holding AG trades at $13.4, +37.6% over the past year. The company is valued at $1.0 B. The stock sits at 64% of its 52-week range of $9–$16, +6.8% versus its 200-day average. Against the S&P 500 it has been ahead on a trailing-13-week view for 4 weeks. — as of 5 August 2026.
What were Aebi Schmidt Holding AG's latest quarterly results?
Aebi Schmidt Holding AG reported revenue of $0.5 B and net profit of $0.0 B for the Mar 26 quarter. Earnings per share were $0.01. The operating margin was 4.3%, 0.3 pp higher than a year earlier. — as of 5 August 2026.
What is Aebi Schmidt Holding AG's revenue?
Aebi Schmidt Holding AG reported revenue of $0.5 B in the Mar 26 quarter, +84.0% year on year. For the full FY25 fiscal year, revenue was $1.5 B (+40.4%). Over the last 2 years revenue compounded at 22.5% a year. — as of 5 August 2026.
What is Aebi Schmidt Holding AG's profit?
Aebi Schmidt Holding AG earned $0.0 B of net profit in the Mar 26 quarter. Full-year FY25 profit was $0.0 B. The operating margin ran 4.3% in the latest quarter. — as of 5 August 2026.
What is Aebi Schmidt Holding AG's market cap?
Aebi Schmidt Holding AG's market capitalisation is $1.0 B at a stock price of $13.4. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
What is Aebi Schmidt Holding AG's P/E ratio?
Aebi Schmidt Holding AG trades at a P/E of 108.5×, at the 95th percentile of its own 1-year range, against a long-run median of 79.8×. This is a comparison with the stock's own history, not a value call — as of 5 August 2026.
Does Aebi Schmidt Holding AG pay a dividend?
Yes — Aebi Schmidt Holding AG declared $0.03 per share for Mar 26 (3 quarters on file, too few for a trailing-twelve-month total). — as of 5 August 2026.
What is Aebi Schmidt Holding AG's dividend per share?
Aebi Schmidt Holding AG's most recently declared dividend is $0.03 per share for Mar 26. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 5 August 2026.
Is Aebi Schmidt Holding AG overvalued?
On its own history, Aebi Schmidt Holding AG looks expensive against its own history: its P/E of 108.5× sits at the 95th percentile of its 1-year range (long-run median 79.8×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 5 August 2026.
How is Aebi Schmidt Holding AG performing?
Aebi Schmidt Holding AG's latest readings are below. Against the S&P 500 it has been ahead on a trailing-13-week view for 4 weeks. This describes what the data did, not a rating. — as of 5 August 2026.
Is Aebi Schmidt Holding AG beating the market?
On recent form, yes — Aebi Schmidt Holding AG has been ahead of the S&P 500 on a trailing-13-week view for 4 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 1.1 years the stock moved +21% against the S&P 500's +24% — behind the index over the full window. — as of 5 August 2026.
Will Aebi Schmidt Holding AG's stock price go up?
This page publishes no price forecast for Aebi Schmidt Holding AG. What it measures instead: the stock price is $13.4. Its P/E of 108.5× sits at the 95th percentile of its own 1-year range. Direction is not something this site claims to know. — as of 5 August 2026.
Is the market betting against Aebi Schmidt Holding AG?
Somewhat — short interest is 4.5% of Aebi Schmidt Holding AG's tradable float, about 5.6 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
Does Aebi Schmidt Holding AG have too much debt?
It is moderate — Aebi Schmidt Holding AG's debt-to-equity is 0.97. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 5 August 2026.
What is Aebi Schmidt Holding AG's capex?
Aebi Schmidt Holding AG spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 5 August 2026.
What is Aebi Schmidt Holding AG's cash flow?
Aebi Schmidt Holding AG generated $0.0 B of operating cash flow in FY25 and $−0.0 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $0.0 B, so operating cash ran ahead of profit. — as of 5 August 2026.
Is Aebi Schmidt Holding AG's profit real cash?
Yes — over the last 3 fiscal years, 220% of Aebi Schmidt Holding AG's reported profit arrived as operating cash. In FY25, operating cash was $0.0 B against reported profit of $0.0 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.
How financially safe is Aebi Schmidt Holding AG?
On the balance sheet, the Z-score reads 1.77 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That is inside the danger band — a real balance-sheet risk. — as of 5 August 2026.
Where is Aebi Schmidt Holding AG in its business cycle?
Aebi Schmidt Holding AG's FY25 operating margin was 4.6%, against a 3-year band of 4.6%–6.4%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 4.3%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the Aebi Schmidt Holding AG story?
The sharpest disagreement: the price moved +37.6% in a year while annual EPS moved −77.6% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is Aebi Schmidt Holding AG a stock worth studying right now?
This is not investment advice. The machine read: Aebi Schmidt Holding AG's price has outrun its earnings. +37.6% in a year against EPS −77.6% — the market is paying now for delivery later. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.